Amphetamine psychosis and psychotic symptoms.
D S Janowsky, C Risch
Psychopharmacology September 1979 DOI: 10.1007/bf00491982 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Case series review Case report Peer reviewed |
|---|---|
| Sample size | 15 |
| Population | Previously reported nonschizophrenic drug abusers in whom amphetamine psychosis was experimentally induced |
| Intervention | Amphetamine |
| Measures | Schneider's first-rank symptoms, World Health Organization Present-State Exam |
| Key findings | Argues that amphetamine psychosis resembles schizophrenia phenomenologically: 7 (possibly 10) of 15 reviewed cases showed Schneider's first-rank symptoms, and all 15 had WHO Present-State Exam symptoms that discriminate schizophrenia. |
Abstract
Amphetamine psychosis has been considered to be a pharmacologic model of schizophrenia. Fifteen previously reported cases were reviewed in which experimental induction of amphetamine psychosis occurred in nonschizophrenic drug abusers. Seven (possibly ten) cases manifested Schneider's first rank symptoms and all had World Health Organization Present-State Exam symptoms which discriminated schizophrenia. This observation draws further parallels between the phenomenology of amphetamine psychosis and schizophrenic symptoms.
Citations in the library
Cited by 9
- Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans Archives of General Psychiatry March 1, 1994
- Comparative and Interactive Human Psychopharmacologic Effects of Ketamine and Amphetamine Archives of General Psychiatry September 1, 2005
- NMDA receptor regulation of memory and behavior in humans Hippocampus October 1, 2001
- Substance-Induced Psychoses: An Updated Literature Review Frontiers in Psychiatry December 23, 2021
- The neurobehavioral pharmacology of ketamine: implications for drug abuse, addiction, and psychiatric disorders. ILAR Journal 2011
and 4 more in the library